Mitchell Saltzberg is a Cardiology physician affiliated with ProHealth Care. OpenAlex indexes 73 publications with 3,321 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9200 W Wisconsin Ave
Cardiovascular Medicine
Milwaukee, WI 532263522
Telephone
414-955-5611Registry record last updated 25 Sept 2017.
Clinical trials
- Utilizing Blood Volume Measurements in the Treatment of Heart Failure Patients
Sponsor: Christiana Care Health Services
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20251 payment
- Amgen Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
82.7%Beta blocker19.2%Metoprolol Succinate64%Carvedilol18%Metoprolol Tartrate11%Atenolol6%Labetalol Hcl2%Part D<11 patientsStatin16.6%Rosuvastatin Calcium49%Atorvastatin Calcium48%Pravastatin Sodium2%Simvastatin1%Part D<11 patients+ 18 more classes in this area
Blood & clotting
12.5%Factor Xa inhibitor7.2%Eliquis93%Xarelto7%Part D<11 patientsP2Y12 inhibitor4.3%Clopidogrel100%Part D≥50 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.8%SGLT2 inhibitor2.3%Jardiance82%Farxiga18%Part D<11 patientsPotassium supplement1.1%Potassium Chloride79%Klor-Con M2021%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- REGIONAL VARIATION IN QUADRUPLE MEDICAL THERAPY AT DISCHARGE FOR PATIENTS WITH HEART FAILURE HOSPITALIZATION: A REPORT FROM THE IMPLEMENT-HF NATIONAL INITIATIVE
Journal of the American College of Cardiology
2024 - Self-management in Heart Failure: The Importance of Self-regulation but not Complexity of Condition
Western Journal of Nursing Research
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”